Thermo Fisher Scientific EBIT

The latest EBIT for TMO.NE is $8.2B as of June 2026. That compares with $4.8B in the prior-year period — up 73.3% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Thermo Fisher Scientific's historical trend and sector peers before judging valuation or financial health.

Over the past year, TMO.NE's EBIT moved from $4.8B to $8.2B — a 73.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Thermo Fisher Scientific's operating scale or balance-sheet position.

Against Healthcare companies, TMO.NE currently prints $8.2B for EBIT, while the sector average sits near $110B. That is roughly 92.3% below the sector mean. Large gaps often invite a closer look at Thermo Fisher Scientific's growth, margins, and balance sheet.

A EBIT figure of $8.2B for TMO.NE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting TMO.NE's EBIT ($8.2B), review year-over-year change from $4.8B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.